



# Endovascular Thrombectomy for Acute Ischemic Stroke

Tasneem F. Hasan<sup>1</sup> · Nathaniel Todnem<sup>2</sup> · Neethu Gopal<sup>3</sup> · David A. Miller<sup>4</sup> · Sukhwinder S. Sandhu<sup>3</sup> · Josephine F. Huang<sup>5</sup> · Rabih G. Tawk<sup>3</sup>

© Springer Science+Business Media, LLC, part of Springer Nature 2019

## Abstract

**Purpose of Review** To review the current evidence supporting the use of endovascular thrombectomy (EVT) for the treatment of acute ischemic stroke (AIS) due to anterior circulation large vessel occlusion (LVO).

**Recent Findings** Recent advances in AIS management by EVT have led to significant reduction in morbidity and mortality in selected patients with LVO within the anterior circulation. Until recently, use of EVT was strictly based on time criteria, within 4.5 to 12 h of symptom onset with many patients presenting with “wake-up” stroke who were not considered for EVT. The positive results of the DAWN and DEFUSE-3 trials have shown benefit in extending the therapeutic window for EVT to 24 and 16 h, respectively, after last known normal (LKN) time in the setting of large ischemic penumbra. These trials represent a paradigm shift in contemporary treatment of AIS, changing from a purely time-based decision to treat to an individualized decision based on clinical and radiographic findings of salvageable tissue.

**Summary** Overall, acute stroke management has evolved considerably over the years from intravenous thrombolysis to include EVT, with paralleled improvements in patient selection and thrombectomy devices. Since the results of the DAWN and DEFUSE-3, EVT is now considered the standard of care in select patients with anterior circulation LVO up to 24 h from LKN time. Despite these developments, post-stroke disability remains pervasive and further studies are warranted in establishing the role of EVT in posterior circulation and distal vessel occlusions, with need for development of new and effective techniques for revascularization of small vessels.

**Keywords** Acute ischemic stroke · Endovascular · Thrombectomy · DAWN · DEFUSE 3 · Stent retrievers

## Introduction

Stroke is the fifth leading cause of death and the number one cause of serious long-term disability in the USA [1, 2]. Every

3 min and 42 s, someone dies of an acute stroke and about 62% of stroke deaths occur outside of a hospital [2]. Geographic disparities in stroke mortality, known as the “stroke belt” in the southeastern USA, have existed since the 1940s, and

---

This article is part of the Topical Collection on *Stroke*

---

✉ Rabih G. Tawk  
Tawk.Rabih@mayo.edu

Tasneem F. Hasan  
thasan@lsuhsc.edu

Nathaniel Todnem  
ntodnem@augusta.edu

Neethu Gopal  
gopal.neethu@mayo.edu

David A. Miller  
miller.david42@mayo.edu

Sukhwinder S. Sandhu  
sandhu.johnny@mayo.edu

Josephine F. Huang  
huang.josephine@mayo.edu

<sup>1</sup> Department of Neurology, Ochsner Louisiana State University Health Sciences Center, Shreveport, LA, USA

<sup>2</sup> Department of Neurologic Surgery, Medical College of Georgia, Augusta, Georgia

<sup>3</sup> Department of Neurologic Surgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA

<sup>4</sup> Department of Diagnostic Radiology, Mayo Clinic, Jacksonville, FL, USA

<sup>5</sup> Department of Neurology, Mayo Clinic, Jacksonville, FL, USA

despite some improvements, these disparities continue [3]. On average, the stroke belt has demonstrated an estimated 30% higher stroke mortality than the rest of the country, while it is nearly 40% higher in the “stroke buckle” regions of North Carolina, South Carolina, and Georgia [4]. Poor functional outcome after an acute stroke can be attributed to the failure in recognizing key symptoms and presenting late to the hospital, often beyond the therapeutic window for management. The estimated total direct medical stroke-related costs from 2015 to 2035 are projected to double from \$36.7 to \$94.3 billion [5].

Recent advances in acute ischemic stroke (AIS) treatment with endovascular thrombectomy (EVT) have demonstrated significant reduction in stroke morbidity and mortality. Historically, the first approved treatment for AIS in 1996 was thrombolysis by intravenous tissue plasminogen activator (IV-tPA). After that, Prolyse in Acute Cerebral Thromboembolism II (PROACT II) demonstrated improved clinical outcomes at 90 days with intra-arterial thrombolysis (IAT) with prourokinase for middle cerebral artery (MCA) occlusions within 6 h of stroke onset. The Interventional Management of Stroke Studies (IMS) suggested that combining IV and IA-tPA was safe and clinically useful in AIS treatment, while the results of five published trials revolutionized the treatment of large vessel occlusions (LVO) amenable to endovascular treatment (EVT) [6–10]. The positive results of the DAWN and DEFUSE-3 trials represent a paradigm shift in contemporary treatment of AIS, moving from a strictly time-based treatment decision to a physiologic-based decision made from advanced imaging characteristics suggestive of salvageable brain, or a so-called clinical-radiographic mismatch. Compared to prior stroke trials, DAWN sought to reach more stroke patients by extending the window for EVT to stroke victims that were previously considered ineligible for EVT. In this review, we provide a brief overview of the landmark EVT trials along with patient selection criteria based on neurovascular imaging, current EVT techniques, unresolved issues, and complications related to EVT.

## Brief Review of Recent Trials

Several randomized EVT trials (SYNTHESIS, IMS III, and MR RESCUE) were reported in 2013 and failed to demonstrate improved patient outcomes following EVT [11–13]. Lessons from these studies led to the design of several studies with more stringent selection criteria. Although vascular reperfusion had been demonstrated earlier, it was not until the emergence of 5 prospective randomized controlled trials (RCTs) in 2015 that the benefits of EVT were clearly demonstrated in selected patients with AIS [6–10]. The decision for EVT was still based strictly on time criteria, within 4.5 to 12 h of symptom onset. Patients with late-presenting stroke symptoms, unwitnessed stroke onset, or stroke symptoms discovered upon awakening were not eligible

for EVT based on these studies. Recently, the DAWN and DEFUSE-3 trials showed benefit in extending the therapeutic window to 24 and 16 h, respectively, after last known normal (LKN) time [14••, 15••]. These landmark EVT trials are summarized in Table 1. The HERMES collaboration [16] was an effort to pool patient-level data for 1287 patients from the 5 positive EVT trials including MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, and EXTEND-IA to assess whether EVT was efficacious across the various included populations. EVT was shown to reduce disability at 90 days, and the number-needed-to-treat with EVT to reduce disability by one level on the modified Rankin Scale (mRS) for one patient was 2.6.

## Patient Selection Criteria for EVT

Patient selection is crucial for improving the outcomes of EVT. Clinically, patients with National Institutes of Health Stroke Scale (NIHSS) > 6 or with a lower score and significant aphasia should be considered for EVT [17]. Imaging criteria continue to evolve with implementation of variable modalities from non-contrast computed tomography (NCCT) and magnetic resonance imaging (MRI) to CT/MR angiogram (CTA/MRA) and CT/MR perfusion (CTP/MRP) [17]. Favorable imaging parameters include an Alberta Stroke Program Computed Tomography Score (ASPECTS) of 6–10, a significant area of mismatch on CTP or MRP, a core infarct < 70 ml, and evidence of anterior circulation LVO with good collaterals on CTA/MRA [18]. Patients with these criteria presenting within 24 h from LKN should be considered for EVT without delay. Outside these established parameters, the decision to pursue EVT is often clinician-dependent with a variety of influencing factors that differ among centers and clinicians.

Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT) is a multicenter, observational, prospective study implementing a protocol to obtain imaging and clinical variables known to affect clinical outcomes after EVT. The goal of the study is to evaluate and compare the selection criteria currently utilized for EVT and identify the criteria that will provide the highest predictive ability in selecting patients with anterior circulation LVO. The study enrolled 500 patients (250 for EVT and 250 for control) ≤ 8 h from LKN time and collected imaging and clinical data, and follow-up data at 90 days. Patients with CTA-proven LVO in the internal carotid artery (ICA) or M1/M2 middle cerebral artery (MCA) location, NIHSS ≥ 6 points, and mRS score 0–1 were included. Primary outcome measure comprised of functional outcome at 90 days, while secondary outcome measures included rate of reperfusion and safety at 90 days as measured by the incidence of hemorrhage, mortality, hematoma, infection, or vascular injury. The study started recruiting participants in 2016 and was completed in May 2018 [19].

**Table 1** Landmark endovascular revascularization trials in acute ischemic stroke

	MR CLEAN [10]	ESCAPE [9]	SWIFT PRIME [6]	EXTEND-IA [7]	REVASCAT [8]	DAWN [14••]	DEFUSE-3 [15••]
Study type	PROBE	PROBE	PROBE	PROBE	PROBE	PROBE	PROBE
(N =)	502	316	196	70	206	206	182
Age	≥ 18	≥ 18	18–80	≥ 18	18–85	≥ 18	18–90
Treatment arm	IA UK/tPA/dev-ice + IV-tPA	Stent retriever + IV-tPA	Stent retriever + IV-tPA	Stent retriever + IV-tPA	Stent retriever + IV-tPA	Trevo retriever + IV-tPA	Trevo Retriever/Solitaire revascularization device/Penumbra thrombectomy system + IV-tPA
Control arm	IV-tPA	IV-tPA	IV-tPA	IV-tPA	IV-tPA	IV-tPA	IV-tPA
Premorbid condition	None	Barthel index ≥ 90	mRS 0–1	mRS 0–1	mRS 0–1	mRS 0–1	mRS 0–2
Median time from stroke onset to groin puncture (min)	260	200	224	210	269	60—randomization to puncture	28—randomization to puncture
Inclusion criteria	≥ 2 ICA, M1, M2, A1, or A2	> 5 MCA trunk and immediate branches and intracranial ICA	8–29 Intracranial ICA, M1, or both	None ICA or MCA	≥ 6 Intracranial ICA or MI	≥ 10 Intracranial ICA and/or MCA-M1	≥ 6 ICA or M1; carotid occlusions can be cervical or intracranial, without or without tandem MCA lesion
Vessel occlusion	CT, MRI, CTA, MRA, DSA	NCCT, mCTA	NCCT, CTA, MRA, MR	NCCT, CTA, CTP	NCCT, MR	NCCT, MRI, MRA, CTA	CTA, MRA, CTP, MRP, MR DWI
Neuroimaging modalities and specific criteria	No specific criteria	Small infarct core (ASPECTS 6–10); good-to-moderate collateral flow	Small infarct core (ASPECTS > 5)	Evidence of salvageable tissue and ischemic core < 70 ml on CTP	Absence of large ischemic core; ASPECTS > 7	MR DWI, CTP < 1/3 MCA territory involved	Target mismatch profile: initial infarct volume (ischemic core) < 70 ml, a ratio of volume of ischemic tissue to initial infarct volume of ≥ 1.8, and absolute volume of potential reversible ischemia (penumbra) ≥ 15 ml
NIHSS	88	72.4	88	86	65.7	84—Modified TIC1 ≥ 2b 72.6—original TIC1 ≥ 2b 10.4—TIC1 3	13—TIC1 2a 57—TIC1 2b 19—TIC1 3
Outcome (EVT vs control)	58.7	72.4	88	86	65.7	84—Modified TIC1 ≥ 2b 72.6—original TIC1 ≥ 2b 10.4—TIC1 3	13—TIC1 2a 57—TIC1 2b 19—TIC1 3

**Table 1** (continued)

	MR CLEAN [10]	ESCAPE [9]	SWIFT PRIME [6]	EXTEND-IA [7]	REVASCAT [8]	DAWN [14••]	DEFUSE-3 [15••]
mRS 0–2 at 90 days (%)	32.6 vs 19.1 (P < 0.05)	53 vs 29.3 (P < 0.001)	60 vs 35 (P < 0.001)	71 vs 40 (P = 0.01)	44 vs 28 (OR 2.1)	49 vs 13 (PPS > 0.999); utility-weighted mRS mean score—5.5 vs 3.4 (PPS > 0.999); NNT—2 and 2.8 for lower disability and functional independence, respectively	45 vs 17 (OR 2.67; P < 0.001)
Symptomatic ICH (%)	7.7 vs 6.4	3.6 vs 2.7	0 vs 3	11 vs 15	1.9 vs 1.9	6 vs 3	7 vs 4
Mortality (%)	18.9 vs 18.4	10.4 vs 19	9 vs 12	9 vs 20	19 vs 16	19 vs 18	14 vs 26

ASPECTS Alberta Stroke Program Early Computed Tomography Score, CT computed tomography, CTA computed tomography angiography, CTP computed tomography perfusion, DWI diffusion-weighted imaging, IA intra-arterial, ICA internal carotid artery, IV-tPA intravenous recombinant tissue-plasminogen activator, M1 first segment of middle cerebral artery, M2 second segment of middle cerebral artery, mCTA multiphasic computed tomography angiography, MRA magnetic resonance angiography, MRP magnetic resonance perfusion, mRS modified Rankin Scale, NCCT non-contrast computed tomography, NIHSS National Institute of Health Stroke Scale, NNT number-needed-to-treat, PPS posterior probability of superiority, TICI thrombolysis in cerebral infarction

## Neurovascular Imaging for EVT

Rapid neurovascular imaging is pivotal in identifying eligible patients for EVT. Recent advancements in neuroimaging have allowed for improved assessment of risks/benefits of EVT and appropriate triage of patients based on specific clinical and radiological features.

NCCT is the first-line and most cost-effective imaging tool used in the setting of an acute stroke [20]. NCCT is critical to help guide the decision for IV-tPA after excluding intracranial hemorrhage. In patients with early AIS, NCCT may appear normal or can show subtle findings such as hypodensity due to cytotoxic edema, loss of gray-white differentiation, cortical swelling, hyperdense MCA sign, or effacement of sulci. When NCCT is performed < 6 h after stroke onset, the prevalence of early CT findings is 61% and the sensitivity of NCCT continues to increase 24 h after AIS [21]. Early evidence of infarction on CT suggests a worse prognosis and is associated with poor functional outcome [21]. Patients unlikely to recover after thrombolytic therapy may be identified using ASPECTS on NCCT, which is a standardized method for quantifying topographically early ischemic changes in the anterior circulation [22]. ASPECTS is calculated using 2 standard axial CT cuts—one at the level of the thalamus and basal ganglia and the other just rostral to the basal ganglia—and by dividing the MCA territory into 10 regions (Table 2) with 1 point subtracted from 10 for ischemic changes noted in each region. A normal NCCT has an ASPECTS of 10, while a patient with diffuse ischemic changes across the MCA territory has a score of 0. In a study of 156 patients with anterior circulation ischemia treated with IV-tPA, an ASPECTS of ≤ 7 was associated with functional dependence and death at 3 months. The sensitivity and specificity of ASPECTS in predicting functional outcome were 78% and 96% for AIS and 90% and 61% for symptomatic ICH [22]. Nonetheless, ASPECTS is not applicable to lacunar strokes or strokes outside the MCA territory, such as strokes of the brainstem or cerebellum.

**Table 2** ASPECTS score

	Axial CT cuts	Regions
Ganglionic ASPECTS	At the level of the caudate head or below	M1–M3, insula, caudate nucleus, lentiform nuclei, internal capsule
Supraganglionic ASPECTS	Above the level of the caudate head, including the body and tail of the caudate nucleus	M4–M6

ASPECTS Alberta Stroke Program Early Computed Tomography Score, CT computed tomography

## Advanced Neurovascular Imaging

MR diffusion-weighted imaging (DWI), non-invasive angiogram (CTA/MRA), and perfusion imaging represent advanced imaging tools for triage of AIS once NCCT excludes hemorrhage or large established infarct. MRI can identify stroke subgroup patients that may benefit from EVT [23], and various MRI sequences are combined (DWI, apparent diffusion coefficient [ADC], fluid-attenuated inversion recovery [FLAIR], and gradient echo [GRE]) to provide details on infarct size and chronicity (acute, subacute, chronic) [24]. Patient limiting factors regarding the utility of MRI include the following: reduced availability afterhours, extensive time required for imaging, presence of implanted metallic objects (e.g., pacemaker), need for sedation in anxious patients, risk of gadolinium-induced nephrogenic systemic fibrosis in patients with end-stage renal disease. MRI limiting factors include table weight capacity and bore diameter capacity. Transfer to another facility with an open MRI would not be feasible due to time constraints. However, in centers where MRI is readily available, protocols utilizing T1 and T2 sequences with DWI, perfusion-weighted imaging (PWI), and GRE are reliable in diagnosing both acute ischemic and hemorrhagic strokes emergently and obviate the need for emergent CT [25]. In one study, the MRI protocol utilized solely during EVT triage had a total imaging time of 5 min and 10 s and included DWI, GRE, MRA time-of-flight, and MRP sequences [26]. DWI offers greater sensitivity (91–100%) and specificity (86–100%) in estimating the volume of infarcted tissue < 6 h from symptom onset [27] and can detect ischemia within 3 to 30 min of symptom onset [28–30]. In the setting of subacute ischemic stroke, DWI changed the management in 14% of cases by clarifying the diagnosis and localizing the vascular territory [31]. The presence of multiple DWI lesions on baseline imaging is associated with an increased risk of early recurrence [32–34], while multiple DWI lesions of variable ages are an independent predictor of future ischemic events [35].

CTA and MRA are non-invasive advanced imaging modalities that provide information about blood vessels in three dimensions and can identify the site of vascular occlusion, proximal access, and degree of collateral circulation. The American Society of Intervention and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) grading scale is widely used to assess collateral circulation [36]. While CTA requires the use of IV contrast and exposure to radiation, MRA time-of-flight technology can be used to visualize blood flow within the vasculature without IV contrast. CTA can be completed in seconds, while MRA may take several minutes. In patients with chronic kidney disease, pregnancy, or allergy to IV contrast, CTA is generally avoided and time of flight MRA is preferred. When performed within 24 h, DWI with MRA improves early diagnostic accuracy of ischemic stroke subtypes [37]. Limitations of MRA are similar to those mentioned earlier with MRI. In the setting of intracranial LVO,

the sensitivity and specificity for CTA range from 92 to 100% and 82 to 100% and from 86 to 97% and 62 to 91% for contrast-enhanced MRA, respectively [38]. Conventional digital subtraction angiography (DSA) remains the gold standard to assess collateral circulation given the small caliber of these vessels. However, its routine use for diagnostic purposes is limited by its invasive nature and long procedural times [39].

CTP and MRP provide an excellent estimation of salvageable tissue and can recognize the presence and location of LVO with correlating angiographic imaging studies. In one study, MRP and DWI alone were found to have a sensitivity of 96% and specificity of 98% for accurate EVT triage where DWI identified the presence of small core infarction and MRP delineated salvageable tissue and identified the presence and location of LVO [26]. Multimodal CT utilizes 3 techniques, including NCCT, CTA, and CTP, and when combined, it improves detection of acute infarction and decreases door to EVT time [40–43]. Perfusion imaging utilizes IV contrast boluses and times its passage through the brain to obtain a whole brain blood perfusion map [44]. It quantifies the amount of contrast agent reaching the brain tissue after a fast IV bolus. Integrating the amount of contrast entering the brain during the first pass followed by the time course of arrival into the tissue and subsequent washout allows construction of cerebral blood volume (CBV), relative cerebral blood flow (rCBF), and mean transit time (MTT) maps. The average transit time for blood through a specific region of the brain is the MTT and depends on the time required for the contrast to travel from the arterial inflow to the venous outflow, while the time to maximum (Tmax) is the time to peak and reflects a delay in the arrival of the contrast bolus to ischemic tissue [24]. Alternatively, arterial spin labeling is a non-ionizing MRI technique for measuring tissue perfusion by magnetically labeling arterial water protons as an endogenous tracer and identifies perfusion defects and diffusion-perfusion mismatches [45].

The utility of perfusion imaging has been advocated by several practices for years. EXTEND IA and SWIFT PRIME utilized CTP per protocol and patients were noted to have better outcomes compared to other studies that utilized NCCT with ASPECTS and CTA, including REVASCAT and ESCAPE [6–9]. Similarly, the DAWN and DEFUSE-3 trials provided level 1 evidence for utilization of perfusion imaging in patient selection for EVT and demonstrated positive results [14•, 15•]. Similarly, patients who had a favorable perfusion profile compared to those that did not and underwent EVT had better outcomes in the CRISP study [46]. On the contrary, other studies reported no significant difference in clinical outcomes when CTP was utilized compared to NCCT [47, 48].

## Brief Review of Current Techniques

EVT for managing AIS from LVO are evolving alongside the rapidly evolving technology. Most of the currently deployed

techniques involve the use of either a third-generation stent retrieval device, a technique of direct aspiration, or a multimodal approach combining the two techniques such as “Solumbra.” The most significant variations among the current techniques include sedation modality, device selection, decision to use a balloon guide catheter (BGC), and technical nuances in stent deployment and retrieval. A recent review from an anonymous survey of 80 Society of Neurointerventional Surgery members regarding EVT techniques reported that direct aspiration without a BGC was the favored technique (41.1%) followed by the Solumbra technique without a BGC (32.4%) and lastly the Solumbra with a BGC (11.8%) [49]. While some prefer using the initial technique for every patient, the selected technique needs to be based on the location and extent of the vascular occlusion with suspected clot characteristics, such as clot length and surmised composition. Such algorithms may include removing softer clots with a stent retriever without aspiration versus removing more fibrin-rich clots with Solumbra technique, but more studies are needed to elucidate which technique is best for each patient.

### Sedation Modality

Three RCTs, the 128-patient General or Local Anesthesia in Intra-Arterial Therapy trial (GOLIATH), the 150-patient Sedation Versus Intubation for Endovascular Stroke Treatment trial (SIESTA), and the 90-patient Anesthesia During Stroke trial (AnStroke), have been published since 2017 comparing the outcomes of EVT with conscious sedation versus general endotracheal anesthesia (GETA) [50–52]. All 3 trials concluded that there was similar efficacy and safety margins. The GOLIATH trial reported no significant difference in procedural time, post-operative pneumonia, length of stay, or reperfusion rate in either group. The SIESTA trial reported increased rate of hypothermia (32.9% vs 9.1%;  $P < 0.001$ ), delayed extubation (49.3% vs 6.5%;  $P < 0.001$ ), and pneumonia (13.7% vs 3.9%;  $P = 0.03$ ) in the GETA group. Both the SIESTA and the AnStroke trials reported no significant difference in overall mortality or neurological outcome in either group. There was a 14.3–15.6% conversion from conscious sedation to GETA with movement and severe agitation being the most common reasons for conversion to general anesthesia. A meta-analysis of these 3 trials and 19 observational studies reported no difference in procedural time, but a higher likelihood of death or respiratory complications in the GETA group [53]. In our practice, we attempt conscious sedation first and convert to general anesthesia in patients who are agitated and poorly cooperative and in patients who develop emesis to prevent aspiration. Larger studies are needed to provide recommendations on superiority of either anesthesia modality.

### Stent Retrievers

Stent retrievers are cylindrical devices that consist of a self-expanding stent mounted on a wire and deployed within the thrombus through a catheter. They immediately push the clot against the arterial walls and re-establish blood flow to the brain in 80 to 90% of cases. The stent is typically deployed for a few minutes to engage the thrombus within its tines and the wire is pulled back to retrieve the thrombus. Since 2015, several large RCTs provided evidence that EVT with a third-generation device is superior to medical management. There are now several devices available with the Solitaire (ev3/ Covidien, Irvine, CA) and Trevo (Stryker Neurovascular, Fremont, CA) being the most commonly used in recent trials including MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, EXTEND-IA, DAWN, and DEFUSE-3. The EmboTrap II (Cerenovus, Irvine, CA) recently obtained FDA approval and appears in early reports to have equivalent safety and efficacy [54, 55]. There is insufficient data to determine superiority of any single device with several active clinical trials for newer devices.

### Direct Aspiration

This thrombectomy technique utilizes a large bore distal access catheter with suction applied at the face of the clot. Compared to stent retrievers, using A Direct Aspiration First Pass Technique (ADAPT) may be as effective with comparable functional outcomes. A retrospective study reported significantly higher rate of good clinical outcome (mRS 0–2) at 90 days in anterior circulation LVO using the ADAPT technique versus stent retrieval (55.6% vs 30.9%;  $P = 0.015$ ) [56]. Another retrospective analysis reported equivalent TICI 2b/3 reperfusion and 90-day mRS scores with a reduction in procedural time and material costs (\$6000–\$7000 per case) when using the ADAPT technique first [57]. In 2017, The Contact Aspiration Versus Stent Retriever for Successful Revascularization (ASTER) multicenter study found no significant difference in reperfusion rates (mTICI 2b/3 85.4% [ $n = 164$ ] vs 83.1% [ $n = 157$ ]; OR, 1.20; 95% CI 0.68–2.10;  $P = 0.53$ ) with similar occurrence of adverse events (symptomatic ICH in 5.3% vs 6.5% and new AIS in a different vascular territory in 5.3% vs 8.5%) [58].

### Combined Modality Techniques

Combined techniques are commonly used in modern clinical practice especially for patients with long segment occlusions and for intracranial ICA occlusions. The “switching strategy” is a modality in which a direct aspiration first pass is made followed by a stent retrieval to remove any residual thrombus. This modality was first reported in 2013 with improved recanalization and no significant difference in time, complications, or

hemorrhage rates [59]. The most commonly used technique is Solumbra, which derives its name from the simultaneous use of the Solitaire stent retriever and the Penumbra aspiration system [60]. The technique is frequently described in the literature with many variations in practice using different stent retrieval devices and different guide catheters with or without a BGC.

The theoretical benefit of combining stent retrievers with catheter aspiration is that the stent can allow immediate restoration of flow through the occlusion after deployment and the continuous suction through an aspiration catheter will minimize distal emboli preventing new stroke in distal territories. The large bore aspiration catheter can also provide another tool for removal of additional clots. The flow typically stops within the catheter when a clot is engaged, and the catheter is pulled back proximally until restoration of good blood flow. The catheter is aspirated to wash out any potential debris and distal access can be re-established from it making subsequent thrombectomy attempts more efficient [61]. Although techniques for clot retrieval are rapidly evolving, there is a growing number of combined modality techniques using stent retrievers and aspiration with slight modifications to improve outcomes. Indeed, there are several variables with clots including size, consistency, and distributions with too few studies to determine superiority of any single technique. Three of the most recently published are as follows: Continuous aspiration prior to intracranial vascular embolectomy (CAPTIVE) [62], Aspiration-Retrieval Technique for Stroke (ARTS) [63], and Stent-Retriever Assisted Vacuum-locked Extraction (SAVE) [64, 65].

### Stent Deployment Techniques

The classic deployment of a stent retriever involves a simple unsheathing of the stent by pulling back the microcatheter allowing the stent to passively expand within the thrombus. The Active Push Deployment (APD) and Push and Fluff Technique (PFT) have been described as possible improvements in classic stent deployment in which the stent is pushed out of the microcatheter, increasing radial expansion and possibly further increasing vessel wall apposition. The PFT technique was described using the Trevo device, which is completely radiopaque allowing the entire structure to be visualized during opening and reported higher rates of first-pass recanalization (54% vs 32.6%;  $P < 0.01$ ) and lower number of passes. In vitro analysis showed PFT with improved wall apposition and up to 75% greater device diameter [66]. Similarly, the APD technique showed widening of the Trevo and Solitaire devices in a retrospective review of 130 patients treated with multiple devices with TICI 2b/3 reperfusion in 88% of patients and 65% with complete reperfusion [67].

The bare wire thrombectomy (BWT) technique describes complete retraction of the microcatheter before clot retrieval to increase aspiration catheter's effectiveness [68]. The SAVE technique describes a distally placed stent retriever with 2/3 of the

stent distal to the clot combined with a proximal aspiration catheter, which are removed as a unit. Early reports for the SAVE technique have been very successful especially for terminal ICA clots. A retrospective study reported first-pass mTICI 3 reperfusion in 23/32 patients (72%) with a mean groin puncture to reperfusion time of 36.0 min  $\pm$  15.8 and mTICI 3 in 25/32 cases (78%) with a maximum of 3 attempts. Successful reperfusion (mTICI  $\geq$  2b) was achieved in all patients [64, 65, 69]. In our practice, we attempt to advance the suction catheter over the microcatheter for direct aspiration of the clot to reduce the required technical steps and to improve the time interval for revascularization. When this proves difficult with tortuous anatomy, we use a stent retriever as an anchor and by pulling on the microcatheter and straightening its course, advancement of the suction catheter against the clot is remarkably facilitated. We also attempt to retrieve the clots locally by pulling the stent retriever in the suction catheter and avoid pulling them against the blood flow. Additional clots are retrieved with the suction catheter still against the clot and the catheter is retrieved slowly under aspiration until restoration of flow. This is followed by aspiration of the catheter until the catheter is free of clots and decision to obtain another pass is based on contrast injection while the suction catheter is maintained close to the occlusion site.

### Balloon Guide Catheters

BGCs can also be used to obtain flow arrest or flow reversal during device retrieval to decrease the chances of thrombus fragmentation and distal migration. Although some studies showed decreased procedure times and increased revascularization rates with first pass, the use of BGC increases the steps for its preparation and deployment and requires a large access (an 8fr sheath) [70]. The Proximal Balloon Occlusion Together with Direct Thrombus Aspiration during Stent Retriever Thrombectomy (PROTECT) technique describes proximal balloon occlusion with flow arrest combined with multimodal thrombus aspiration and stent retrieval thrombectomy. Compared to direct aspiration, the PROTECT technique resulted in shorter procedure times (29 vs 40 min;  $P = 0.002$ ) and higher rate of TICI 3 reperfusion (70% vs 39%) [71]. In our practice, we use BGC in cases with proximal ICA occlusions especially when the occlusion extends over a long segment as these cases have a large clot burden and a high risk of distal embolization.

## Future Considerations for Stroke Care

### Posterior Circulation

The role of EVT for revascularization of the posterior circulation remains largely unknown. Small series such as the Tama-Registry of Acute Thrombectomy (TREAT) study [72] retrospectively

studied 48 patients with acute basilar artery occlusion who underwent EVT with stent retrievers and aspiration devices with successful reperfusion in 98% of patients. More than 41% achieved good outcome (mRS 0–2) while 54.2% achieved moderate outcome (mRS 0–3). Major obstacles continue to face clinicians for establishing EVT selection criteria for posterior circulation. This is related to complex anatomy of the brainstem and higher prevalence of anatomical variation in the posterior circulation compared to the anterior circulation [73]. Moreover, CT and CTP studies have reduced sensitivity in detection of posterior fossa infarcts and posterior circulation ischemic changes particularly in the midbrain, and initial stroke symptoms referable to the posterior circulation may not trigger emergent EVT consideration because of low scoring NIHSS [74]. Therefore, the role of EVT for posterior circulation ischemia still needs to be established.

### Distal Occlusions

The challenges of EVT in patients with distal occlusions are multifold. Conventional imaging has limitations in detecting distal vessel occlusions and incorporation of multiphase CTA and advanced perfusion reconstructions can increase the sensitivity and specificity for identification of distal vessel occlusion [75, 76]. Other challenges are related to the heterogeneity of clinical symptoms, disabling versus non-disabling and low versus high eloquence [77–79]. Other challenges are related to the limitations of endovascular devices since suction catheters and stent retrievers may not be used safely and effectively in distal occlusions beyond the M2 segment [77–79]. Currently, there is a promising and growing body of evidence that mechanical thrombectomy is safe and more efficacious than standard of care in M2 occlusions [77–79]. The role of IA-tPA, microwire manipulation of the clots within small vessels, and small suction catheters still needs to be determined.

### Tandem Occlusions

Tandem occlusions consist of proximal carotid artery occlusions along with concomitant distal intracranial artery occlusion. These cases are particularly challenging given the amount of clot burden and the variability of the underlying pathology that could be related to carotid dissection, carotid stenosis, or to cardiogenic source with a large thrombus that occludes the ICA. In general, presenting symptoms are related to the distal occlusion within the intracranial circulation and patients present with high NIHSS scores especially with occlusion of the ICA terminus. This is related to reduced anterograde flow in the ACA, which limits the leptomeningeal collateralization to the MCA distal territory and involvement of the proximal M1 with corresponding territory of deep ganglia [80]. Both anterograde (proximal to distal revascularization with treatment of the proximal occlusion before distal revascularization) and retrograde (distal to proximal revascularization with treatment of the distal

occlusion prior to the proximal occlusion) methods have been reported for the treatment of tandem occlusions with no unanimity on the optimal strategy to approach these cases [81, 82]. A multimodal approach with use of IV-tPA followed by extracranial ICA angioplasty and intracranial mechanical thrombectomy has been suggested in selected patients [80]. However, AIS related to tandem occlusions pose a significant challenge as they generally have decreased chances of reperfusion due to heavy clot burden and hemodynamic instability resulting in suboptimal drug delivery [83–85]. When the terminus is not occluded, we favor revascularization of the distal occlusion first as it allows to restore the flow in MCA from contralateral supply via retrograde flow from ACA and we tend to utilize a proximal balloon protection to reduce the risk of additional or recurrent distal embolization.

### Complications

Data reports a broad range of procedure-related complications from 4 to 31% [6–10, 86–92]. These complications include groin hematoma (RCT 3.6% vs non-RCT 1.4%), spontaneous ICH (RCT 4.0–4.3% vs non-RCT 5.3%), subarachnoid hemorrhage (RCT 2.5% vs non-RCT 2%), intraventricular hemorrhage (RCT 1%), device failure including stent detachment or displacement (non-RCT 1.2%), arterial perforation (RCT 1.3% vs non-RCT 2%), arterial dissection (RCT 2% vs non-RCT 3%), vasospasm (RCT 10% vs non-RCT 4%), carotid-cavernous fistula (non-RCT 2.4%), distal arterial embolization (RCT 6% vs non-RCT 4.5%), early mortality  $\leq 7$  days (RCT 9% vs non-RCT 9%), and late mortality  $\leq 90$  days (RCT 15% vs non-RCT 18%) [6–10, 86–89, 93–99]. In addition to the abovementioned complications, there exists the risk of radiation-induced cancer in about 1 in 3000 patients age  $> 60$ , owing to the combined radiation from CT, CTA, and endovascular management [100].

### Conclusion

Acute stroke management has evolved considerably over the years from IV thrombolysis to include EVT with a variety of techniques. EVT is currently considered standard of care in selected patients with LVO within the anterior circulation. The window of treatment has been extended to patients presenting within 24 h from LKN time. The Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT 2) will further evaluate the safety and efficacy of EVT with stent retrievers (Trevo, Solitaire, EmboTrap) in patients treated within 24 h from LKN time who present with a large core infarct and ASPECTS 3–10, rCBF  $< 40\%$  (0–100 cc), mismatch volume  $\geq 15$  cc, and mismatch ratio  $\geq 1.8$  [101]. The specific imaging

criteria and EVT techniques continue to evolve with the advent of new devices using suction catheters and stent retrievers individually or combined to achieve revascularization efficiently and to improve patient outcomes. Despite these developments, disability from stroke remains high and further development is needed in stroke management including optimal imaging modality and revascularization of posterior circulation and distal branches for eloquent brain.

### Compliance with Ethical Standards

**Conflict of Interest** Tasneem F. Hasan, Nathaniel Todnem, Neethu Gopal, David A. Miller, Sukhwinder S. Sandhu, Josephine F. Huang, and Rabih G. Tawk declare that they have no conflict of interest.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

### References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Centers for Disease Control and Prevention (CDC). Prevalence and most common causes of disability among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep.* 2009;58(16):421–6.
2. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation.* 2019;139(10):e56–e528. <https://doi.org/10.1161/CIR.0000000000000659>.
3. Howard G, Evans GW, Pearce K, Howard VJ, Bell RA, Mayer EJ, et al. Is the stroke belt disappearing? An analysis of racial, temporal, and age effects. *Stroke.* 1995;26(7):1153–8.
4. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. *Stroke.* 2014;45(1):315–53. <https://doi.org/10.1161/01.str.0000437068.30550.cf>.
5. Khavjou O, Phelps D, Leib A. Projections of cardiovascular disease prevalence and costs: 2015–2035. *North Carolina: RTI International;* 2016.
6. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med.* 2015;372(24):2285–95. <https://doi.org/10.1056/NEJMoa1415061>.
7. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015;372(11):1009–18. <https://doi.org/10.1056/NEJMoa1414792>.
8. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* 2015;372(24):2296–306. <https://doi.org/10.1056/NEJMoa1503780>.
9. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015;372(11):1019–30. <https://doi.org/10.1056/NEJMoa1414905>.
10. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med.* 2015;372(1):11–20. <https://doi.org/10.1056/NEJMoa1411587>.
11. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. *N Engl J Med.* 2013;368(10):904–13. <https://doi.org/10.1056/NEJMoa1213701>.
12. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. *N Engl J Med.* 2013;368(10):893–903. <https://doi.org/10.1056/NEJMoa1214300>.
13. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. *N Engl J Med.* 2013;368(10):914–23. <https://doi.org/10.1056/NEJMoa1212793>.
- 14•• . Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med.* 2018;378(1):11–21. <https://doi.org/10.1056/NEJMoa1706442> **Findings from this study suggest that patients presenting with acute stroke with last known normal between 6 and 24 h and with a mismatch between clinical deficit and infarct have better outcomes for disability at 90 days with thrombectomy plus standard care than standard care alone.**
- 15•• . Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med.* 2018;378(8):708–18. <https://doi.org/10.1056/NEJMoa1713973> **Findings from this study suggest that endovascular thrombectomy plus standard medical therapy result in better functional outcomes than standard medical therapy alone in patients presenting for ischemic stroke with last known normal between 6 and 16 h and with proximal middle cerebral artery or internal carotid artery occlusion and an area of ischemic tissue, not yet infarcted.**
16. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet.* 2016;387(10029):1723–31. [https://doi.org/10.1016/S0140-6736\(16\)00163-X](https://doi.org/10.1016/S0140-6736(16)00163-X).
17. Hasan TF, Rabinstein AA, Middlebrooks EH, Haranhalli N, Silliman SL, Meschia JF, et al. Diagnosis and management of acute ischemic stroke. *Mayo Clin Proc.* 2018;93(4):523–38. <https://doi.org/10.1016/j.mayocp.2018.02.013>.
18. Campbell BCV, Donnan GA, Mitchell PJ, Davis SM. Endovascular thrombectomy for stroke: current best practice and future goals. *Stroke Vasc Neurol.* 2016;1(1):16–22. <https://doi.org/10.1136/svn-2015-000004>.
19. [ClinicalTrials.gov](https://clinicaltrials.gov). Optimizing Patient’s Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT). 2016. <https://clinicaltrials.gov/ct2/show/NCT02446587>. Accessed May 25 2019.
20. Wardlaw JM, Seymour J, Cairns J, Keir S, Lewis S, Sandercock P. Immediate computed tomography scanning of acute stroke is cost-effective and improves quality of life. *Stroke.* 2004;35(11):2477–83. <https://doi.org/10.1161/01.STR.0000143453.78005.44>.
21. Wardlaw JM, Mielke O. Early signs of brain infarction at CT: observer reliability and outcome after thrombolytic treatment—systematic review. *Radiology.* 2005;235(2):444–53. <https://doi.org/10.1148/radiol.2352040262>.

22. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. *Lancet*. 2000;355(9216):1670–4. [https://doi.org/10.1016/s0140-6736\(00\)02237-6](https://doi.org/10.1016/s0140-6736(00)02237-6).
23. Kohrman M, Schellinger PD. Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. *Radiology*. 2009;251(3):627–33. <https://doi.org/10.1148/radiol.2513081074>.
24. Lin MP, Liebeskind DS. Imaging of ischemic stroke. *Continuum (Minneapolis Minn)*. 2016;22(5, Neuroimaging):1399–423. <https://doi.org/10.1212/CON.0000000000000376>.
25. Kang DW, Chalela JA, Dunn W, Warach S, Investigators NI-SSC. MRI screening before standard tissue plasminogen activator therapy is feasible and safe. *Stroke*. 2005;36(9):1939–43. <https://doi.org/10.1161/01.STR.0000177539.72071.f0>.
26. Wolman DN, Iv M, Wintermark M, Zaharchuk G, Marks MP, Do HM, et al. Can diffusion- and perfusion-weighted imaging alone accurately triage anterior circulation acute ischemic stroke patients to endovascular therapy? *J Neurointerv Surg*. 2018;10(12):1132–6. <https://doi.org/10.1136/neurintsurg-2018-013784>.
27. Gonzalez RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf G, et al. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. *Radiology*. 1999;210(1):155–62. <https://doi.org/10.1148/radiology.210.1.r99ja02155>.
28. Li F, Han S, Tatlisumak T, Carano RA, Irie K, Sotak CH, et al. A new method to improve in-bore middle cerebral artery occlusion in rats: demonstration with diffusion- and perfusion-weighted imaging. *Stroke*. 1998;29(8):1715–9 discussion 9-20.
29. Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-Hellinger FR, et al. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. *Radiology*. 1996;199(2):391–401. <https://doi.org/10.1148/radiology.199.2.8668784>.
30. Baird AE, Warach S. Magnetic resonance imaging of acute stroke. *J Cereb Blood Flow Metab*. 1998;18(6):583–609. <https://doi.org/10.1097/00004647-199806000-00001>.
31. Schulz UG, Briley D, Meagher T, Molyneux A, Rothwell PM. Diffusion-weighted MRI in 300 patients presenting late with subacute transient ischemic attack or minor stroke. *Stroke*. 2004;35(11):2459–65. <https://doi.org/10.1161/01.STR.0000143455.55877.b9>.
32. Kang DW, Latour LL, Chalela JA, Dambrosia J, Warach S. Early ischemic lesion recurrence within a week after acute ischemic stroke. *Ann Neurol*. 2003;54(1):66–74. <https://doi.org/10.1002/ana.10592>.
33. Wen HM, Lam WW, Rainer T, Fan YH, Leung TW, Chan YL, et al. Multiple acute cerebral infarcts on diffusion-weighted imaging and risk of recurrent stroke. *Neurology*. 2004;63(7):1317–9. <https://doi.org/10.1212/01.wnl.0000140490.22251.b6>.
34. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM, et al. Silent ischemia in minor stroke and TIA patients identified on MR imaging. *Neurology*. 2005;65(4):513–7. <https://doi.org/10.1212/01.wnl.0000169031.39264.ff>.
35. Sylaja PN, Coutts SB, Subramaniam S, Hill MD, Eliasziw M, Demchuk AM, et al. Acute ischemic lesions of varying ages predict risk of ischemic events in stroke/TIA patients. *Neurology*. 2007;68(6):415–9. <https://doi.org/10.1212/01.wnl.0000252938.76188.52>.
36. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, von Kummer R, Saver JL, et al. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke*. 2013;44(9):2650–63. <https://doi.org/10.1161/STROKEAHA.113.001972>.
37. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. *Stroke*. 2000;31(5):1081–9.
38. Latchaw RE, Alberts MJ, Lev MH, Connors JJ, Harbaugh RE, Higashida RT, et al. Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. *Stroke*. 2009;40(11):3646–78. <https://doi.org/10.1161/STROKEAHA.108.192616>.
39. Qureshi AI. New grading system for angiographic evaluation of arterial occlusions and recanalization response to intra-arterial thrombolysis in acute ischemic stroke. *Neurosurgery*. 2002;50(6):1405–14; discussion 14-5. <https://doi.org/10.1097/00006123-200206000-00049>.
40. Ezzeddine MA, Lev MH, McDonald CT, Rordorf G, Oliveira-Filho J, Aksoy FG, et al. CT angiography with whole brain perfused blood volume imaging: added clinical value in the assessment of acute stroke. *Stroke*. 2002;33(4):959–66.
41. Kloska SP, Nabavi DG, Gaus C, Nam EM, Klotz E, Ringelstein EB, et al. Acute stroke assessment with CT: do we need multimodal evaluation? *Radiology*. 2004;233(1):79–86. <https://doi.org/10.1148/radiol.2331030028>.
42. Hopyan J, Ciarallo A, Dowlatshahi D, Howard P, John V, Yeung R, et al. Certainty of stroke diagnosis: incremental benefit with CT perfusion over noncontrast CT and CT angiography. *Radiology*. 2010;255(1):142–53. <https://doi.org/10.1148/radiol.09091021>.
43. Campbell BC, Weir L, Desmond PM, Tu HT, Hand PJ, Yan B, et al. CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke. *J Neurol Neurosurg Psychiatry*. 2013;84(6):613–8. <https://doi.org/10.1136/jnnp-2012-303752>.
44. Allmendinger AM, Tang ER, Lui YW, Spektor V. Imaging of stroke: part 1, perfusion CT—overview of imaging technique, interpretation pearls, and common pitfalls. *AJR Am J Roentgenol*. 2012;198(1):52–62. <https://doi.org/10.2214/AJR.10.7255>.
45. Chalela JA, Alsop DC, Gonzalez-Atavales JB, Maldjian JA, Kasner SE, Detre JA. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. *Stroke*. 2000;31(3):680–7.
46. Lansberg MG, Christensen S, Kemp S, Mlynash M, Mishra N, Federau C, et al. Computed tomographic perfusion to predict response to recanalization in ischemic stroke. *Ann Neurol*. 2017;81(6):849–56. <https://doi.org/10.1002/ana.24953>.
47. Hassan AE, Zacharatos H, Rodriguez GJ, Vazquez G, Miley JT, Tummala RP, et al. A comparison of computed tomography perfusion-guided and time-guided endovascular treatments for patients with acute ischemic stroke. *Stroke*. 2010;41(8):1673–8. <https://doi.org/10.1161/STROKEAHA.110.586685>.
48. Sheth KN, Terry JB, Nogueira RG, Horev A, Nguyen TN, Fong AK, et al. Advanced modality imaging evaluation in acute ischemic stroke may lead to delayed endovascular reperfusion therapy without improvement in clinical outcomes. *J Neurointerv Surg*. 2013;5(Suppl 1):i62–5. <https://doi.org/10.1136/neurintsurg-2012-010512>.
49. Mehta T, Male S, Quinn C, Kallmes DF, Siddiqui AH, Turk A, et al. Institutional and provider variations for mechanical thrombectomy in the treatment of acute ischemic stroke: a survey analysis. *J Neurointerv Surg*. 2019;11:884–90. <https://doi.org/10.1136/neurintsurg-2018-014614>.
50. Sorensen LH, Speiser L, Karabegovic S, Yoo AJ, Rasmussen M, Sorensen KE, et al. Safety and quality of endovascular therapy under general anesthesia and conscious sedation are comparable: results from the GOLIATH trial. *J Neurointerv Surg*. 2019. <https://doi.org/10.1136/neurintsurg-2019-014712>.

51. Schonemberger S, Uhlmann L, Hacke W, Schieber S, Mundiyanapurath S, Purrucker JC, et al. Effect of conscious sedation vs general anesthesia on early neurological improvement among patients with ischemic stroke undergoing endovascular thrombectomy: a randomized clinical trial. *JAMA*. 2016;316(19):1986–96. <https://doi.org/10.1001/jama.2016.16623>.
52. Lowhagen Henden P, Rentzos A, Karlsson JE, Rosengren L, Leiram B, Sundeman H, et al. General anesthesia versus conscious sedation for endovascular treatment of acute ischemic stroke: the AnStroke trial (anesthesia during stroke). *Stroke*. 2017;48(6):1601–7. <https://doi.org/10.1161/STROKEAHA.117.016554>.
53. Brinjikji W, Pasternak J, Murad MH, Cloft HJ, Welch TL, Kallmes DF, et al. Anesthesia-related outcomes for endovascular stroke revascularization: a systematic review and meta-analysis. *Stroke*. 2017;48(10):2784–91. <https://doi.org/10.1161/STROKEAHA.117.017786>.
54. Mattle HP, Scarrott C, Claffey M, Thomson J, Macho J, Riedel C, et al. Analysis of revascularisation in ischaemic stroke with EmboTrap (ARISE I study) and meta-analysis of thrombectomy. *Interv Neuroradiol*. 2019;25(3):261–70. <https://doi.org/10.1177/1591019918817406>.
55. Valente I, Nappini S, Renieri L, Pedicelli A, Lozupone E, Colosimo C, et al. Initial experience with the novel EmboTrap II clot-retrieving device for the treatment of ischaemic stroke. *Interv Neuroradiol*. 2019;25(3):271–6. <https://doi.org/10.1177/1591019918819709>.
56. Delgado Almandoz JE, Kayan Y, Young ML, Fease JL, Scholz JM, Milner AM, et al. Comparison of clinical outcomes in patients with acute ischemic strokes treated with mechanical thrombectomy using either Solumbra or ADAPT techniques. *J Neurointerv Surg*. 2016;8(11):1123–8. <https://doi.org/10.1136/neurintsurg-2015-012122>.
57. Stapleton CJ, Leslie-Mazwi TM, Torok CM, Hakimelahi R, Hirsch JA, Yoo AJ, et al. A direct aspiration first-pass technique vs stentriever thrombectomy in emergent large vessel intracranial occlusions. *J Neurosurg*. 2018;128(2):567–74. <https://doi.org/10.3171/2016.11.JNS161563>.
58. Lapergue B, Blanc R, Gory B, Labreuche J, Duhamel A, Marnat G, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial. *JAMA*. 2017;318(5):443–52. <https://doi.org/10.1001/jama.2017.9644>.
59. Kang DH, Kim YW, Hwang YH, Park J, Hwang JH, Kim YS. Switching strategy for mechanical thrombectomy of acute large vessel occlusion in the anterior circulation. *Stroke*. 2013;44(12):3577–9. <https://doi.org/10.1161/STROKEAHA.113.002673>.
60. Samaniego EA, Roa JA, Limaye K, Adams HP Jr. Mechanical thrombectomy: emerging technologies and techniques. *J Stroke Cerebrovasc Dis*. 2018;27(10):2555–71. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.025>.
61. Dumont TM, Mokin M, Sorkin GC, Levy EI, Siddiqui AH. Aspiration thrombectomy in concert with stent thrombectomy. *BMJ Case Rep*. 2013;2013:bcr2012010624. <https://doi.org/10.1136/bcr-2012-010624>.
62. McTaggart RA, Tung EL, Yaghi S, Cutting SM, Hemendinger M, Gale HI, et al. Continuous aspiration prior to intracranial vascular embolectomy (CAPTIVE): a technique which improves outcomes. *J Neurointerv Surg*. 2017;9(12):1154–9. <https://doi.org/10.1136/neurintsurg-2016-012838>.
63. Massari F, Henninger N, Lozano JD, Patel A, Kuhn AL, Howk M, et al. ARTS (aspiration-retriever technique for stroke): initial clinical experience. *Interv Neuroradiol*. 2016;22(3):325–32. <https://doi.org/10.1177/1591019916632369>.
64. Brehm A, Maus V, Tsogkas I, Colla R, Hesse AC, Gera RG, et al. Stent-retriever assisted vacuum-locked extraction (SAVE) versus a direct aspiration first pass technique (ADAPT) for acute stroke: data from the real-world. *BMC Neurol*. 2019;19(1):65. <https://doi.org/10.1186/s12883-019-1291-9>.
65. Maus V, Behme D, Kabbasch C, Borggrefe J, Tsogkas I, Nikoubashman O, et al. Maximizing first-pass complete reperfusion with SAVE. *Clin Neuroradiol*. 2018;28(3):327–38. <https://doi.org/10.1007/s00062-017-0566-z>.
66. Haussen DC, Rebello LC, Nogueira RG. Optimizing clot retrieval in acute stroke: the push and fluff technique for closed-cell stentriever. *Stroke*. 2015;46(10):2838–42. <https://doi.org/10.1161/STROKEAHA.115.010044>.
67. Wiesmann M, Brockmann MA, Heringer S, Muller M, Reich A, Nikoubashman O. Active push deployment technique improves stent/vessel-wall interaction in endovascular treatment of acute stroke with stent retrievers. *J Neurointerv Surg*. 2017;9(3):253–6. <https://doi.org/10.1136/neurintsurg-2016-012322>.
68. Nikoubashman O, Alt JP, Nikoubashman A, Busen M, Heringer S, Brockmann C, et al. Optimizing endovascular stroke treatment: removing the microcatheter before clot retrieval with stent-retrievers increases aspiration flow. *J Neurointerv Surg*. 2017;9(5):459–62. <https://doi.org/10.1136/neurintsurg-2016-012319>.
69. Maus V, Henkel S, Riabikin A, Riedel C, Behme D, Tsogkas I, et al. The SAVE technique : large-scale experience for treatment of intracranial large vessel occlusions. *Clin Neuroradiol*. 2018. <https://doi.org/10.1007/s00062-018-0702-4>.
70. Velasco A, Buerke B, Stracke CP, Berkemeyer S, Mosimann PJ, Schwandt W, et al. Comparison of a balloon guide catheter and a non-balloon guide catheter for mechanical thrombectomy. *Radiology*. 2016;280(1):169–76. <https://doi.org/10.1148/radiol.2015150575>.
71. Maergerlein C, Monch S, Boeckh-Behrens T, Lehm M, Hedderich DM, Berndt MT, et al. PROTECT: PProximal balloon Occlusion TOgether with direCt Thrombus aspiration during stent retriever thrombectomy—evaluation of a double embolic protection approach in endovascular stroke treatment. *J Neurointerv Surg*. 2018;10(8):751–5. <https://doi.org/10.1136/neurintsurg-2017-013558>.
72. Kaneko J, Ota T, Tagami T, Unemoto K, Shigeta K, Amano T, et al. Endovascular treatment of acute basilar artery occlusion: Tama-REgistry of Acute Thrombectomy (TREAT) study. *J Neurol Sci*. 2019;401:29–33. <https://doi.org/10.1016/j.jns.2019.04.010>.
73. Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR. Symptoms and signs of posterior circulation ischemia in the new England medical center posterior circulation registry. *Arch Neurol*. 2012;69(3):346–51. <https://doi.org/10.1001/archneurol.2011.2083>.
74. Rentzos A, Karlsson JE, Lundqvist C, Rosengren L, Hellstrom M, Wikholm G. Endovascular treatment of acute ischemic stroke in the posterior circulation. *Interv Neuroradiol*. 2018;24(4):405–11. <https://doi.org/10.1177/1591019918762320>.
75. Kunz WG, Fabritius MP, Sommer WH, Hohne C, Scheffler P, Rotkopf LT, et al. Effect of stroke thrombolysis predicted by distal vessel occlusion detection. *Neurology*. 2018;90(20):e1742–e50. <https://doi.org/10.1212/WNL.000000000000519>.
76. Yu AY, Zerna C, Assis Z, Holodinsky JK, Randhawa PA, Najm M, et al. Multiphase CT angiography increases detection of anterior circulation intracranial occlusion. *Neurology*. 2016;87(6):609–16. <https://doi.org/10.1212/WNL.0000000000002951>.
77. Sarraj A, Sangha N, Hussain MS, Wisco D, Vora N, Eljovich L, et al. Endovascular therapy for acute ischemic stroke with occlusion of the middle cerebral artery M2 segment. *JAMA Neurol*.

- 2016;73(11):1291–6. <https://doi.org/10.1001/jamaneurol.2016.2773>.
78. Coutinho JM, Liebeskind DS, Slater LA, Nogueira RG, Baxter BW, Levy EI, et al. Mechanical thrombectomy for isolated M2 occlusions: a post hoc analysis of the STAR, SWIFT, and SWIFT PRIME studies. *AJNR Am J Neuroradiol.* 2016;37(4):667–72. <https://doi.org/10.3174/ajnr.A4591>.
  79. Saber H, Narayanan S, Palla M, Saver JL, Nogueira RG, Yoo AJ, et al. Mechanical thrombectomy for acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery: a meta-analysis. *J Neurointerv Surg.* 2018;10(7):620–4. <https://doi.org/10.1136/neurintsurg-2017-013515>.
  80. Dababneh H, Guerrero WR, Khanna A, Hoh BL, Mocco J. Management of tandem occlusion stroke with endovascular therapy. *Neurosurg Focus.* 2012;32(5):E16. <https://doi.org/10.3171/2012.1.FOCUS11350>.
  81. Puri AS, Kuhn AL, Kwon HJ, Khan M, Hou SY, Lin E, et al. Endovascular treatment of tandem vascular occlusions in acute ischemic stroke. *J Neurointerv Surg.* 2015;7(3):158–63. <https://doi.org/10.1136/neurintsurg-2013-011010>.
  82. Mbabuike N, Gassie K, Brown B, Miller DA, Tawk RG. Revascularization of tandem occlusions in acute ischemic stroke: review of the literature and illustrative case. *Neurosurg Focus.* 2017;42(4):E15. <https://doi.org/10.3171/2017.1.FOCUS16521>.
  83. Kim YS, Garami Z, Mikulik R, Molina CA, Alexandrov AV, Collaborators C. Early recanalization rates and clinical outcomes in patients with tandem internal carotid artery/middle cerebral artery occlusion and isolated middle cerebral artery occlusion. *Stroke.* 2005;36(4):869–71. <https://doi.org/10.1161/01.STR.0000160007.57787.4c>.
  84. National Institute of Neurological D, Stroke rt PASSG. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995;333(24):1581–7. <https://doi.org/10.1056/NEJM199512143332401>.
  85. Rangel-Castilla L, Rajah GB, Shakir HJ, Shallwani H, Gandhi S, Davies JM, et al. Management of acute ischemic stroke due to tandem occlusion: should endovascular recanalization of the extracranial or intracranial occlusive lesion be done first? *Neurosurg Focus.* 2017;42(4):E16. <https://doi.org/10.3171/2017.1.FOCUS16500>.
  86. Muir KW, Ford GA, Messow CM, Ford I, Murray A, Clifton A, et al. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. *J Neurol Neurosurg Psychiatry.* 2017;88(1):38–44. <https://doi.org/10.1136/jnnp-2016-314117>.
  87. Minnerup J, Wersching H, Teuber A, Wellmann J, Eyding J, Weber R, et al. Outcome after thrombectomy and intravenous thrombolysis in patients with acute ischemic stroke: a prospective observational study. *Stroke.* 2016;47(6):1584–92. <https://doi.org/10.1161/STROKEAHA.116.012619>.
  88. Serles W, Gattringer T, Mutzenbach S, Seyfang L, Trenkler J, Killer-Oberpfalzer M, et al. Endovascular stroke therapy in Austria: a nationwide 1-year experience. *Eur J Neurol.* 2016;23(5):906–11. <https://doi.org/10.1111/ene.12958>.
  89. Urra X, Abilleira S, Dorado L, Ribo M, Cardona P, Millan M, et al. Mechanical thrombectomy in and outside the REVASCAT trial: insights from a concurrent population-based stroke registry. *Stroke.* 2015;46(12):3437–42. <https://doi.org/10.1161/STROKEAHA.115.011050>.
  90. Gasco G, Lobotesis K, Machi P, Maldonado I, Vendrell JF, Riquelme C, et al. Stent retrievers in acute ischemic stroke: complications and failures during the perioperative period. *AJNR Am J Neuroradiol.* 2014;35(4):734–40. <https://doi.org/10.3174/ajnr.A3746>.
  91. Behme D, Gondecki L, Fiethen S, Kowoll A, Mpotsaris A, Weber W. Complications of mechanical thrombectomy for acute ischemic stroke—a retrospective single-center study of 176 consecutive cases. *Neuroradiology.* 2014;56(6):467–76. <https://doi.org/10.1007/s00234-014-1352-0>.
  92. Kuntze Soderqvist A, Kaijser M, Soderman M, Holmin S, Wahlgren N, Andersson T. Mechanical thrombectomy in acute ischemic stroke—experience from 6 years of practice. *Neuroradiology.* 2014;56(6):477–86. <https://doi.org/10.1007/s00234-014-1353-z>.
  93. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol.* 2016;15(11):1138–47. [https://doi.org/10.1016/S1474-4422\(16\)30177-6](https://doi.org/10.1016/S1474-4422(16)30177-6).
  94. Nikoubashman O, Jungbluth M, Schurmann K, Muller M, Falkenburger B, Tauber SC, et al. Neurothrombectomy in acute ischaemic stroke: a prospective single-centre study and comparison with randomized controlled trials. *Eur J Neurol.* 2016;23(4):807–16. <https://doi.org/10.1111/ene.12944>.
  95. McCusker MW, Robinson S, Looby S, Power S, Ti JP, Grech R, et al. Endovascular treatment for acute ischaemic stroke with large vessel occlusion: the experience of a regional stroke service. *Clin Radiol.* 2015;70(12):1408–13. <https://doi.org/10.1016/j.crad.2015.08.007>.
  96. Akpınar SH, Yılmaz G. Periprocedural complications in endovascular stroke treatment. *Br J Radiol.* 2016;89(1057):20150267. <https://doi.org/10.1259/bjr.20150267>.
  97. Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. *Stroke.* 2016;47(9):2331–8. <https://doi.org/10.1161/STROKEAHA.116.013372>.
  98. Alonso de Lecinana M, Martinez-Sanchez P, Garcia-Pastor A, Kawiorski MM, Calleja P, Sanz-Cuesta BE, et al. Mechanical thrombectomy in patients with medical contraindications for intravenous thrombolysis: a prospective observational study. *J Neurointerv Surg.* 2017;9(11):1041–6. <https://doi.org/10.1136/neurintsurg-2016-012727>.
  99. Castano C, Dorado L, Remollo S, Garcia-Bermejo P, Gomis M, Perez de la Ossa N et al. Unwanted detachment of the Solitaire device during mechanical thrombectomy in acute ischemic stroke. *J Neurointerv Surg.* 2016;8(12):1226–1230. <https://doi.org/10.1136/neurintsurg-2015-012156>.
  100. Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. *N Engl J Med.* 2007;357(22):2277–84. <https://doi.org/10.1056/NEJMra072149>.
  101. [ClinicalTrials.gov](https://clinicaltrials.gov). SELECT 2: a Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke. 2019. <https://clinicaltrials.gov/ct2/show/NCT03876457>. Accessed May 25 2019.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.